NASDAQ:ACXP Acurx Pharmaceuticals (ACXP) Stock Forecast, Price & News $1.41 -0.09 (-6.00%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$1.35▼$1.5050-Day Range$1.41▼$2.2252-Week Range$1.35▼$4.61Volume44,419 shsAverage Volume31,582 shsMarket Capitalization$18.34 millionP/E RatioN/ADividend YieldN/APrice Target$13.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Acurx Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside822.0% Upside$13.00 Price TargetShort InterestHealthy0.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.08) to ($0.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.44 out of 5 starsMedical Sector199th out of 976 stocksPharmaceutical Preparations Industry74th out of 453 stocks 3.5 Analyst's Opinion Consensus RatingAcurx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.00, Acurx Pharmaceuticals has a forecasted upside of 822.0% from its current price of $1.41.Amount of Analyst CoverageAcurx Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.06% of the float of Acurx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAcurx Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Acurx Pharmaceuticals has recently decreased by 51.09%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAcurx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcurx Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACXP. Previous Next 3.6 News and Social Media Coverage News SentimentAcurx Pharmaceuticals has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Acurx Pharmaceuticals this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Acurx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acurx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders35.30% of the stock of Acurx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.28% of the stock of Acurx Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Acurx Pharmaceuticals are expected to grow in the coming year, from ($1.08) to ($0.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acurx Pharmaceuticals is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acurx Pharmaceuticals is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcurx Pharmaceuticals has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Acurx Pharmaceuticals (NASDAQ:ACXP) StockAcurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. It is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. The company was incorporated in 2017 and is headquartered in Staten Island, New York.Read More ACXP Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACXP Stock News HeadlinesSeptember 13, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Acurx Pharmaceuticals (ACXP)August 22, 2023 | finance.yahoo.comAcurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023September 28, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...August 15, 2023 | msn.comHC Wainwright & Co. Maintains Acurx Pharmaceuticals (ACXP) Buy RecommendationAugust 15, 2023 | markets.businessinsider.comMaxim Group Remains a Buy on Acurx Pharmaceuticals (ACXP)August 15, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Acurx Pharmaceuticals (ACXP)August 14, 2023 | markets.businessinsider.comAcurx Pharma's Phase 2b Study Of Ibezapolstat In C. Difficile Infection On TrackJuly 24, 2023 | finance.yahoo.comAcurx Pharmaceuticals to Discuss Second Quarter 2023 Financial Results and Provide Business UpdateSeptember 28, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...June 20, 2023 | finance.yahoo.comAcurx Pharmaceuticals to Present at the Emerging Growth Conference on July 12, 2023June 15, 2023 | finance.yahoo.comAcurx Pharmaceuticals to Participate in the Maxim Group LLC Virtual Healthcare Conference on Tuesday, June 20, 2023 to Thursday, June 22, 2023 at 9 am ETMay 17, 2023 | insidermonkey.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q1 2023 Earnings Call TranscriptMay 16, 2023 | finance.yahoo.comAcurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct OfferingMay 15, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Acurx Pharmaceuticals (ACXP)May 12, 2023 | msn.comRecap: Acurx Pharmaceuticals Q1 EarningsMay 12, 2023 | finance.yahoo.comAcurx Pharmaceuticals, Inc. Reports First Quarter 2023 Results and Provides Business UpdateMay 11, 2023 | msn.comA Preview Of Acurx Pharmaceuticals's EarningsMay 5, 2023 | finance.yahoo.comAcurx Pharmaceuticals to Discuss First Quarter 2023 Financial Results and Provide Business UpdateApril 22, 2023 | finance.yahoo.comHere's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn SituationApril 19, 2023 | finance.yahoo.comAcurx Announces Ibezapolstat Scientific Poster and Update on its Pol IIIC Pipeline Presented at ECCMID 2023 Scientific ConferenceApril 12, 2023 | msn.comHC Wainwright & Co. Reiterates Acurx Pharmaceuticals (ACXP) Buy RecommendationApril 11, 2023 | finance.yahoo.comFDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial and Acurx Announces Presentations at ECCMID 2023 Scientific ConferenceMarch 23, 2023 | benzinga.comAcurx Pharmaceuticals Earns Bullish Update From H.C. Wainwright & Co., Affirms BUY Rating And $14 Price TargetMarch 19, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Amgen (AMGN) and Acurx Pharmaceuticals (ACXP)March 18, 2023 | seekingalpha.comAcurx Pharmaceuticals, Inc. (ACXP) Q4 2022 Earnings Call TranscriptMarch 18, 2023 | finance.yahoo.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2022 Earnings Call TranscriptMarch 16, 2023 | msn.comAcurx Pharmaceuticals GAAP EPS of -$0.28 beats by $0.15See More Headlines Receive ACXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acurx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACXP Company Calendar Last Earnings8/14/2023Today9/27/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACXP CUSIPN/A CIK1736243 Webwww.acurxpharma.com Phone917-533-1469FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Forecast$13.00 High Stock Price Forecast$13.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+815.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,090,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-183.90% Return on Assets-142.39% Debt Debt-to-Equity RatioN/A Current Ratio3.06 Quick Ratio3.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.63 per share Price / Book2.25Miscellaneous Outstanding Shares13,010,000Free Float8,414,000Market Cap$18.47 million OptionableNot Optionable Beta-1.00 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Robert J. DeLuccia (Age 77)Co-Founder & Exec. Chairman Comp: $677.19kMr. David P. Luci CPA (Age 56)CPA, Esq., J.D., Co-Founder, Pres, CEO, Corp. Sec. & Director Comp: $655kMr. Robert G. Shawah CPA (Age 56)CPA, Co-Founder & CFO Comp: $375kKey CompetitorsAcer TherapeuticsNASDAQ:ACERVincerx PharmaNASDAQ:VINCNRx PharmaceuticalsNASDAQ:NRXPPurple BiotechNASDAQ:PPBTCatalyst BiosciencesNASDAQ:CBIOView All CompetitorsInstitutional OwnershipOsaic Holdings Inc.Bought 6,000 shares on 8/21/2023Ownership: 0.169%One68 Global Capital LLCBought 13,044 shares on 8/14/2023Ownership: 0.101%Osaic Holdings Inc.Bought 6,000 shares on 8/10/2023Ownership: 0.170%View All Institutional Transactions ACXP Stock - Frequently Asked Questions Should I buy or sell Acurx Pharmaceuticals stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acurx Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ACXP shares. View ACXP analyst ratings or view top-rated stocks. What is Acurx Pharmaceuticals' stock price forecast for 2023? 2 Wall Street analysts have issued 1-year target prices for Acurx Pharmaceuticals' shares. Their ACXP share price forecasts range from $13.00 to $13.00. On average, they expect the company's stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 815.5% from the stock's current price. View analysts price targets for ACXP or view top-rated stocks among Wall Street analysts. How have ACXP shares performed in 2023? Acurx Pharmaceuticals' stock was trading at $3.98 at the beginning of the year. Since then, ACXP shares have decreased by 64.3% and is now trading at $1.42. View the best growth stocks for 2023 here. Are investors shorting Acurx Pharmaceuticals? Acurx Pharmaceuticals saw a drop in short interest during the month of September. As of September 15th, there was short interest totaling 6,700 shares, a drop of 51.1% from the August 31st total of 13,700 shares. Based on an average trading volume of 35,000 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.1% of the company's shares are short sold. View Acurx Pharmaceuticals' Short Interest. When is Acurx Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our ACXP earnings forecast. How were Acurx Pharmaceuticals' earnings last quarter? Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) released its quarterly earnings results on Monday, August, 14th. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01. During the same period last year, the company earned ($0.26) earnings per share. When did Acurx Pharmaceuticals IPO? (ACXP) raised $15 million in an IPO on Friday, June 25th 2021. The company issued 2,500,000 shares at $5.00-$7.00 per share. Alexander Capital, L.P. and Network 1 Financial Securities served as the underwriters for the IPO. What is Acurx Pharmaceuticals' stock symbol? Acurx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACXP." Who are Acurx Pharmaceuticals' major shareholders? Acurx Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Osaic Holdings Inc. (0.17%), Osaic Holdings Inc. (0.17%) and One68 Global Capital LLC (0.10%). Insiders that own company stock include Carl Sailer, David P Luci and Robert J Deluccia. View institutional ownership trends. How do I buy shares of Acurx Pharmaceuticals? Shares of ACXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Acurx Pharmaceuticals' stock price today? One share of ACXP stock can currently be purchased for approximately $1.42. How much money does Acurx Pharmaceuticals make? Acurx Pharmaceuticals (NASDAQ:ACXP) has a market capitalization of $18.47 million. The company earns $-12,090,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. How can I contact Acurx Pharmaceuticals? The official website for the company is www.acurxpharma.com. The company can be reached via phone at 917-533-1469 or via email at davidluci@acurxpharma.com. This page (NASDAQ:ACXP) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.